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Lymphoma incidence, survival and prevalence
2004–2014: sub-type analyses from the UK’s
Haematological Malignancy Research
Network
A Smith1, S Crouch1, S Lax1, J Li1, D Painter1, D Howell1, R Patmore2, A Jack3 and E Roman*,1
1Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, YO10 5DD, UK; 2Queens
Centre for Oncology, Castle Hill Hospital, Hull HU16 5JQ, UK and 3St James’s Institute of Oncology, Leeds Teaching Hospitals
NHS Trust, Leeds LS9 7TF, UK
Background: Population-based information about cancer occurrence and survival are required to inform clinical practice and
research; but for most lymphomas data are lacking.
Methods: Set within a socio-demographically representative UK population of nearly 4 million, lymphoma data (N¼ 5796) are
from an established patient cohort.
Results: Incidence, survival (overall and relative) and prevalence estimates for420 subtypes are presented. With few exceptions,
males tended to be diagnosed at younger ages and have significantly (Po0.05) higher incidence rates. Differences were greatest
at younger ages: the o15 year male/female rate ratio for all subtypes combined being 2.2 (95% CI 1.3–3.4). These gender
differences impacted on prevalence; most subtype estimates being significantly (Po0.05) higher in males than females. Outcome
varied widely by subtype; survival of patients with nodular lymphocyte predominant Hodgkin lymphoma approached that of the
general population, whereas less than a third of those with other B-cell (e.g., mantle cell) or T-cell (e.g., peripheral-T) lymphomas
survived for Z5 years. No males/female survival differences were detected.
Conclusions: Major strengths of our study include completeness of ascertainment, world-class diagnostics and generalisability.
The marked variations demonstrated confirm the requirement for ‘real-world’ data to inform aetiological hypotheses, health-care
planning and the future monitoring of therapeutic changes.
The lymphomas comprise a heterogeneous group of cancers with
diverse aetiologies, treatment pathways and outcomes (Swerdlow
et al, 2008; Campo et al, 2011). Critically for research, appreciation
of the similarities and differences between the various sub-types
only surfaced in recent decades as biological understanding about
the relationship between these complex malignancies, the bone
marrow, the immune system and the cellular and genetic basis of
malignant transformation increased (Harris et al, 2000; Jaffe et al,
2001; Swerdlow et al, 2008; Jaffe, 2009; Campo et al, 2011). Even
now, this area of oncology remains one of the most rapidly
evolving fields; with developments in genomics, diagnostic
technologies and targeted therapies meaning that existing lym-
phoma definitions are continually subject to change (Puvvada et al,
2013; Dunleavy and Wilson, 2014; O’Connor and Tobinai, 2014).
The pace and recency of scientific advances, coupled with the
breadth of laboratory investigations required to make an accurate
diagnosis, mean that dependable comprehensive population-based
information about the underlying patterns of incidence and
survival of clinically meaningful lymphoma subtypes is limited
(Morton et al, 2006; Sant et al, 2010, 2014; Marcos-Gragera et al, 2011;
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Smith et al, 2011; Olszewski and Castillo, 2013; Nabhan et al,
2014). Such ‘real-world’ data are, however, required not only to
inform aetiological hypotheses and plan future health-care services,
but also to monitor the impact of therapeutic changes in the
general patient population. This need is particularly pertinent in
fast-moving areas like haematological oncology where treatment
protocols are subject to rapid change, and ‘gold standard’
randomised controlled trials are invariably restricted to specific
patient sub-groups; often younger patients with fewer co-morbidities
(Rothwell, 2005, 2010; Elting et al, 2006; Janson et al, 2009;
Al-Refaie et al, 2011; Freemantle et al, 2013; Van de Water et al,
2014). Furthermore in some countries, particularly those where
universal health-care coverage is lacking, the likelihood of trial
participation usually varies with socio-economic status, gender and
ethnicity (Murthy et al, 2004; Penberthy et al, 2012; Kwiatkowski
et al, 2013; Mohd Noor et al, 2013; Unger et al, 2013). Such biases
impact on the external validity of experimental treatment trials;
and ‘real-world’ observational data are increasingly being used to
provide context and evaluate treatment effectiveness across the
whole patient population (Sehn et al, 2005; Armstrong, 2012;
Hershman and Wright, 2012; Kodeda et al, 2013; Tripathy et al,
2013; Smith et al, 2014).
In the case of lymphomas, an added dimension is provided by
the fact that the pathways of patients diagnosed with incurable but
comparatively indolent subtypes, such as follicular lymphoma and
marginal zone lymphoma, may begin with a period of ‘active-
monitoring/watch and wait’. The resulting patient pathways can be
complex and diverse, with individual patients differing widely in
their need for, and response to, different treatment regimens; some
having long periods of observation, and others having multiple
courses of chemotherapy (Dreyling et al, 2013, 2014; Michallet
et al, 2013). In such a circumstance, extrapolating survival data
derived from specific treatment trials to the general patient
population is problematic and may result in misleading estimates.
In addition, depending on the data feeds used for case
ascertainment, the fact that some lymphoma patients are not
treated can pose further challenges for cancer registries, and the
frequency estimates (incidence and prevalence) they produce.
The UK’s population-based Haematological Malignancy Research
Network (HMRN) was specifically established in 2004 to address the
needs outlined above, by producing ‘real-time’ generalisable data
that would inform contemporary clinical practice and research
(Smith et al, 2010). With nearly 4 million people, representing 6% of
the UK population, the socio-demographic composition (age,
gender, deprivation) of the regional population mirrors that of the
UK as a whole. All diagnoses (42200 a year) are made and coded by
clinical specialists working within a single integrated haemato-
pathology laboratory, irrespective of the patient’s age, treatment
intent, or management within the National Health Service or private
sector (Smith et al, 2011). With its emphasis on completeness and
utilisation of primary-source information, HMRN’s data are
increasingly being used to provide ‘gold-standard’ information to
facilitate decision making (NCIN/ECSG, 2014; NICE, 2014). The
present paper reports incidence, survival and prevalence estimates
on over 20 lymphoma subtypes traditionally categorised topogra-
phically as being either Hodgkin or non-Hodgkin (World Health
Organization, 1992). Providing the best available up-to-date
population-based information, the lymphomas included were
diagnosed over the period 2004–2012 and followed-up through to
March 2014.
METHODS
Data are from the UK’s population-based Haematological
Malignancy Research Network (www.hmrn.org). Initiated in
2004, full details of its structure, data collection methods and
ethical approvals have been previously described (Smith et al,
2010). Briefly, within HMRN, patient care is provided by 14
hospitals organised into five multi-disciplinary teams; and clinical
practice adheres to national guidelines. As a matter of policy, all
diagnoses are made and coded by clinical specialists at a single
integrated haematopathology laboratory—the Haematological
Malignancy Diagnostic Service (www.hmds.info); cited in the
UK’s Department of Health’s Cancer Reform Strategy (2007) as
‘the model for delivery of complex diagnostic services’. HMRN has
Section 251 support under the NHS Act 2006, and all patients have
full-treatment, response and outcome data collected to clinical trial
standards; all are ‘flagged’ for death and subsequent cancer
registrations at the national Medical Research Information Service
(MRIS) and routinely linked to nationwide information on
Hospital Episode Statistics.
For analytical purposes, area-based population counts were
sourced from the Office National Statistics (Office for National
Statistics, 2001). All analyses were conducted either in the
statistical package Stata 12 (Stata-Corp, 2011) or R (R Core
Team, 2013). Incidence rates and their 95% confidence intervals
(CIs) were estimated by Poisson regression. Directly age-standar-
dised rates (European) were calculated using the Stata command
‘dstdize’ and corresponding standardised sex rate ratios and their
95% confidence intervals were estimated (Jensen, 1991). The
overall survival was calculated using standard time to event
analyses and the program strel (v1.2.7) was used to estimate
relative survival; age- and sex-specific background mortality rates
were obtained from national life tables (Cancer Research UK,
2006). Prevalence estimates (3, 5 and 10 year) and corresponding
confidence intervals were calculated from incidence and survival
data using R’s ‘survival’ and ‘rms’ libraries; 3 and 5 year estimates
were calculated directly from the patient cohort, and Monte-Carlo
simulation techniques were employed to generate the larger
10-year values (Crouch et al, 2014).
RESULTS
The 5796 lymphomas diagnosed September 2004 to August 2012
are distributed by sub-type and gender in Table 1; with frequencies
and median ages at diagnosis being given for subtypes that had 10
or more diagnoses during the 8-year period. The traditional
categories of non-Hodgkin and Hodgkin are shown first, followed
by the more meaningful cell-of-origin groupings. Mature B-cell
malignancies, which comprise around 94.7% (N¼ 5488) of the
total, occurred far more frequently than the rarer T-cell subtypes
(N¼ 308); with diffuse large B-cell lymphoma accounting for
around 4 out of 10 lymphoma diagnoses, followed by the more
indolent follicular and marginal zone subtypes, which when
combined accounted for a further 3 out of 10 lymphoma diagnoses.
As with many other cancers, the likelihood of an individual
being diagnosed with lymphoma increases markedly with age, the
median age at diagnosis being 67.2 years (interquartile range 54.9–
76.5 years) for all patients combined (Table 1). However, unlike
many other cancers, some lymphomas can be diagnosed at any age,
with different subtypes dominating at different ages, as can be seen
more clearly in Figures 1 and 2: Figure 1 showing the age-specific
rates of the main subtypes, and Figure 2 the corresponding
distribution within age classes. Hodgkin and Burkitt lymphomas
dominate the paediatric age range (o15 years), where there were
no cases of follicular lymphoma (youngest patient 19 years),
marginal zone lymphoma (youngest patient 20 years), or mantle
cell lymphoma (youngest patient 39 years) within our population.
By contrast, in those aged 60 years or more, diffuse large B-cell,
marginal-zone and follicular lymphomas accounted for over 80%
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of diagnoses, and the common childhood lymphomas only
occurred occasionally. As with B-cell lymphomas, the rarer T-cell
lymphomas span the full age range, but again there is considerable
heterogeneity by subtype (Table 1): the median age of patients with
ALK-positive anaplastic T-cell lymphoma being 35.6 (IQR 24.3–
43.9) and those with angioimmunoblastic T-cell lymphoma being
71.9 years (IQR 61.6–78.4).
In general, males tend to be diagnosed with B-cell lymphomas
at younger ages than females (Table 1) and, with one or two
exceptions, experience higher rates of disease at all ages; the
male/female sex rate ratio (Figure 2) being highest in those
diagnosed before the age of 15 years (2.2; 95% CI 1.3–3.4).
Indeed, as is evident from Table 2, males are almost three times
as likely to develop some B- and T-cell cancer subtypes: the
European age standardised sex-rate ratios being 2.57 (95% CI
2.3–2.88), 2.95 (95% CI 2.3–3.78), 3.49 (95% CI 1.53–7.97) and
2.96 (95% CI 2.28–3.84), respectively, for mantle cell, Burkitt,
lymphocyte-rich classical Hodgkin and lymphocyte predomi-
nant nodular Hodgkin (B-cell lymphomas); and 2.97 (95% CI
1.12–7.89) and 2.69 (95% CI 1.62–4.46), respectively, for
ALK-positive anaplastic large cell and mycosis fungoides
(T-cell lymphomas).
Amongst the lymphomas, there are marked outcome differences
by subtype, as is evident from the 5-year overall and relative
survival estimates given in Table 3 and the survival curves shown
for the eight main B-cell lymphoma categories in Figure 3. At one
extreme, the survival of patients with nodular lymphocyte
predominant Hodgkin lymphoma approaches that of the general
population (Figure 3); and with no deaths among women in the
follow-up period, gender-specific data are not presented in Table 3.
By contrast, around three-quarters of patients with mantle cell
lymphoma die within 5 years of their diagnosis; the similarity
between the overall and relative survival curves confirming that
most patients with this cancer die from their disease. With respect
to differences between males and females, no statistically
significant differences are evident either for overall or relative
survival; the sex-specific relative survival estimates, which take
account of the fact that women tend to live longer than men,
Table 1. Lymphoma numbers and median ages (IQR) at diagnosis: Haematological Malignancy Research Network (HMRN)
2004–2012
Total diagnoses Males Females
No (%)
Median age
(IQR) No (%)
Median age
(IQR) No (%)
Median age
(IQR)
P Median age
difference
(male versus
female)
All lymphomas 5796 (100) 67.2 (54.9–76.5) 3086 (100) 66.0 (53.1–75.4) 2710 (100) 68.8 (56.7–77.7) 0.001
Non-Hodgkin 4961 (85.6) 69.1 (58.9–77.6) 2614 (84.7) 67.9 (57.9–76.5) 2347 (86.6) 70.5 (60.7–78.5) 0.001
Hodgkin 835 (14.4) 41.3 (26.8–63.5) 472 (15.3) 42.0 (27.7–61.5) 363 (13.4) 39.6 (26.0–65.8) 0.358
B-cell 5488 (94.7) 67.4 (55.1–76.6) 2914 (94.4) 66.1 (53.4–75.5) 2574 (95.0) 68.9 (56.9–77.7) 0.001
DLBCL 2373 (40.9) 70.0 (59.6–78.2) 1243 (40.3) 68.4 (58.0–76.9) 1130 (41.7) 71.4 (61.4–79.6) 0.001
DLBCL, NOS 2312 (39.9) 70.0 (59.7–78.2) 1208 (39.1) 68.4 (58.4–77.0) 1104 (40.7) 71.4 (61.3–79.5) 0.001
T-cell/histiocyte-rich 32 (0.6) 65.5 (52.7–77.3) 17 (0.6) 59.8 (44.1–74.4) 15 (0.6) 71.3 (61.5–78.9) 0.188
Plasmablastic 24 (0.4) 70.9 (54.4–78.2) 15 (0.5) 69.2 (53.4–75.1) 9 (0.3) 76.0 (68.4–81.5) 0.482
MZL 983 (17.0) 72.4 (63.8–79.2) 537 (17.4) 71.2 (63.5–78.6) 446 (16.5) 73.4 (64.1–79.5) 0.021
Systemic MZL 772 (13.3) 72.9 (65.3–79.4) 434 (14.1) 72.2 (64.6–79.2) 338 (12.5) 73.7 (66.2–79.8) 0.117
Extranodal MZL 211 (3.6) 68.8 (57.2–77.8) 103 (3.3) 66.5 (55.8–76.9) 108 (4.0) 72.4 (57.9–79.4) 0.017
FL 923 (15.9) 64.9 (55.8–73.3) 412 (13.4) 63.1 (55.0–72.8) 511 (18.9) 66.3 (56.5–73.8) 0.001
Follicular 897 (15.5) 65.0 (55.9–73.3) 397 (12.9) 63.2 (55.4–72.8) 500 (18.5) 66.4 (56.6–73.8) 0.001
Follicular, large cell 26 (0.4) 58.5 (50.0–71.9) 15 (0.5) 59.6 (44.4–74.9) 11 (0.4) 57.4 (52.2–71.3) 0.805
MCL 247 (4.3) 73.5 (64.3–80.3) 159 (5.2) 71.0 (61.2–78.9) 88 (3.2) 75.8 (67.3–82.6) 0.006
BL 103 (1.8) 52.2 (16.9–64.8) 76 (2.5) 39.4 (12.1–63.9) 27 (1.0) 56.8 (38.9–69.2) 0.026
Intermediate DLBCL/CHLa 24 (0.4) 59.3 (34.2–72.1) 15 (0.5) 54.5 (26.2–66.0) 9 (0.3) 71.8 (55.8–77.9) 0.212
CHL 737 (12.7) 40.9 (26.3–64.1) 400 (13.0) 42.0 (27.3–62.8) 337 (12.4) 38.1 (25.7–65.6) 0.144
Nodular sclerosis CHL 545 (9.4) 37.0 (25.0–59.4) 283 (9.2) 39.5 (25.6–59.4) 262 (9.7) 33.9 (24.5–59.5) 0.006
Mixed cellularity CHL 173 (3.0) 59.2 (36.1–70.6) 102 (3.3) 53.2 (34.3–69.2) 71 (2.6) 65.4 (40.5–72.5) 0.004
Lymphocyte-rich CHL 18 (0.3) 49.3 (35.9–59.7) 14 (0.5) 47.8 (34.5–57.7) 4 (0.1) 59.4 (51.5–61.9) 0.195
Lymphocyte predominant nodular HL 98 (1.7) 43.6 (29.9–59.1) 72 (2.3) 41.6 (30.3–55.7) 26 (1.0) 55.2 (27.2–65.9) 0.096
T-cell 308 (5.3) 65.1 (51.8–74.8) 172 (5.6) 63.9 (49.1–73.6) 136 (5.0) 68.3 (54.4–76.6) 0.070
Peripheral—common, unspecified 91 (1.6) 68.5 (52.9–77.2) 57 (1.8) 65.9 (49.8–73.9) 34 (1.3) 71.6 (59.1–81.7) 0.295
Angioimmunoblastic 55 (0.9) 71.9 (61.6–78.4) 20 (0.6) 67.7 (55.2–75.9) 35 (1.3) 72.9 (64.6–80.1) 0.281
Anaplastic large cell 46 (0.8) 59.2 (41.3–74.3) 28 (0.9) 54.0 (40.1–73.4) 18 (0.7) 63.5 (43.2–75.7) 0.334
ALK-negative 27 (0.5) 69.0 (57.4–81.6) 15 (0.5) 72.4 (61.0–77.6) 12 (0.4) 64.4 (54.4–86.5) 0.407
ALK-positive 16 (0.3) 35.6 (24.3–43.9) 12 (0.4) 39.7 (27.3–44.4) 4 (0.1) 25.5 (15.3–36.6) 0.275
Mycosis fungoides 39 (0.7) 65.8 (53.9–75.8) 28 (0.9) 67.0 (53.8–76.0) 11 (0.4) 63.0 (54.8–70.6) 0.513
Primary cutaneous CD30þ LPD 37 (0.6) 52.9 (39.4–70.5) 19 (0.6) 61.5 (39.0–73.1) 18 (0.7) 49.3 (39.4–62.6) 0.233
Enteropathy-type 24 (0.4) 62.7 (58.6–68.1) 13 (0.4) 61.6 (58.0–64.0) 11 (0.4) 65.0 (60.6–71.4) 0.343
Abbreviations: ALK¼ anaplastic lymphoma kinase; BL¼Burkitt lymphoma; CHL¼ classical Hodgkin lymphoma; DLBCL¼diffuse large B-cell lymphoma; FL¼ follicular lymphoma;
IQR¼ interquartile range; LPD¼ lymphoproliferative disorders; MCL¼mantle cell lymphoma; MZL¼marginal zone lymphoma; NOS¼ not otherwise specified.
a
Cases classified 2009–2012 only.
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tending to be more similar to each other than the overall survival
estimates (Table 3).
Prevalence estimates (3, 5 and 10 year) generated from
incidence and survival data are given for the main lymphoma
subtypes in Table 4; and the sex-specific estimates of the main
B-cell lymphoma subtypes are shown side-by-side in Figure 4. Data
for lymphocyte predominant nodular Hodgkin lymphoma are not
shown because the numbers of deaths were too few to generate
reliable estimates. For all lymphomas combined, prevalence ranged
from 48.0 (95% CI 45.8–50.3) per 100 000 population within 3
years of diagnosis, through to 72.5 (95% CI 69.7–75.3) per 100 000
within 5 years and 123.7 (95% CI 120.0–127.4) within 10 years. For
some lymphomas, such as diffuse large B-cell lymphoma where the
corresponding 3-, 5- and 10-year point estimates are 17.6, 25.9 and
43.3 per 100 000, respectively, the prevalent pools will contain
individuals who have been cured of their cancer; the proportion
falling as the time-frame lengthens. On the other hand, for chronic
incurable lymphomas like follicular lymphoma where the 3, 5 and
10 year estimates are 9.7, 14.8 and 25.2, respectively, the prevalent
pools will be comprised of individuals who are either being actively
monitored or who are receiving treatment for their disease.
The male to female prevalence differences evident in Table 4
and Figure 4, are largely due to differences in both age at diagnosis
and underlying incidence patterns: males tend to be diagnosed at
younger ages (Table 1) and have higher disease incidence levels
(Table 2). Given these, it is perhaps not surprising that, with the
exception of follicular lymphoma, the 3, 5 and 10 year prevalence
estimates for males tend to be higher than those of females across
all main subtypes; resulting in 10-year prevalence estimates
for all lymphomas combined of 138.3 (95% CI 132.7–144.0) and
109.9 (95% CI 105.1–114.8) per 100 000 for males and females
respectively—a difference of almost 30 per 100 000. It is also
important to note that these differences are not due to differential
survival: the 5-year relative survival estimates for all lymphomas
combined being 67.2 (95% CI 65.0–69.2) and 67.8 (95% CI 65.5–
69.9) respectively (Table 3).
DISCUSSION
This paper presents contemporary sex-specific incidence, pre-
valence and survival estimates for more than 20 lymphoma
subtypes, providing much needed ‘real-world’ data to better inform
practitioners and researchers. To our knowledge, this is the first
time that reliable population-based occurrence and survival
estimates for several clinically meaningful lymphoma subtypes
have been presented side-by-side. The benefits of this are
immediately apparent. Within categories that are often lumped
together, outcome varied markedly from one subtype to another;
patients with some disease subtypes tending to have near normal
lifespan, whereas those with others often died rapidly from their
disease. Furthermore, strong differences between males and
females were observed with respect to subtype incidence and
prevalence frequencies, as well as age at cancer onset. Such
differences have clear implications not only for aetiological
hypotheses and clinical practice, but also for health service
planning.
With respect to descriptive patterns, mature B-cell neoplasms
dominated our data; the commonest subtype being diffuse large
B-cell lymphoma (median diagnostic age 70.0 years), which
accounted for 40% of the total, and the rarest T-cell ALK-positive
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Table 2. Lymphoma crude and age standardised (European) incidence rates per 100000 (95% confidence interval): Haematological Malignancy Research Network (HMRN)
2004–2012
Total Diagnoses Males Females
Annual rate (95% CI) per 100000 Annual rate (95% CI) per 100000 Annual rate (95% CI) per 100000
Crude
Age standardised
(European)
Crude
Age standardised
(European)
Crude
Age standardized
(European)
Age std. sex rate
ratio (M/F)
P M/F age std rate
difference
All lymphomas 20.29 (19.77–20.82) 16.84 (16.68–17.00) 22.3 (21.52–23.10) 19.95 (19.7–20.2) 18.40 (17.71–19.11) 14.29 (14.08–14.49) 1.40 (1.37–1.42) o0.0001
Non-Hodgkin 17.37 (16.89–17.86) 14.01 (13.87–14.16) 18.89 (18.17–19.63) 16.63 (16.4–16.85) 15.93 (15.3–16.59) 11.92 (11.74–12.11) 1.39 (1.37–1.42) o0.0001
Hodgkin 2.92 (2.73–3.13) 2.83 (2.70–2.90) 3.41 (3.11–3.73) 3.32 (3.21–3.43) 2.46 (2.22–2.73) 2.36 (2.27–2.45) 1.41 (1.34–1.48) o0.0001
B-cell 19.21 (18.71–19.73) 15.92 (15.77–16.08) 21.06 (20.3–21.83) 18.82 (18.57–19.06) 17.48 (16.81–18.16) 13.56 (13.36–13.75) 1.39 (1.36–1.42) o0.0001
DLBCL 8.31 (7.98–8.65) 6.60 (6.60–6.70) 8.98 (8.49–9.50) 7.85 (7.69–8.01) 7.67 (7.23–8.13) 5.60 (5.47–5.73) 1.40 (1.36–1.45) o0.0001
DLBCL, NOS 8.09 (7.77–8.43) 6.43 (6.33–6.53) 8.73 (8.24–9.24) 7.63 (7.47–7.79) 7.50 (7.06–7.95) 5.48 (5.36–5.60) 1.39 (1.35–1.44) o0.0001
T-cell/histiocyte-rich 0.30 (0.20–0.42) 0.10 (0.07–0.12) 0.33 (0.19–0.52) 0.12 (0.07–0.17) 0.27 (0.15–0.45) 0.08 (0.05–0.11) 1.52 (0.82–2.81) 0.183
Plasmablastic 0.11 (0.07–0.17) 0.07 (0.05–0.09) 0.11 (0.06–0.18) 0.10 (0.06–0.14) 0.12 (0.06–0.23) 0.04 (0.02–0.06) 2.44 (1.22–4.90) 0.012
MZL 3.44 (3.23–3.66) 2.62 (2.56–2.68) 3.88 (3.56–4.22) 3.30 (3.20–3.41) 3.03 (2.75–3.32) 2.11 (2.03–2.19) 1.56 (1.49–1.64) o0.0001
Systemic MZL 2.70 (2.52–2.90) 2.03 (1.97–2.08) 3.14 (2.85–3.45) 2.64 (2.55–2.73) 2.29 (2.06–2.55) 1.57 (1.51–1.64) 1.68 (1.59–1.78) o0.0001
Extranodal MZL 0.74 (0.64–0.85) 0.60 (0.57–0.63) 0.74 (0.61–0.90) 0.67 (0.61–0.73) 0.73 (0.60–0.89) 0.54 (0.49–0.59) 1.23 (1.08–1.40) 0.002
FL 3.23 (3.03–3.45) 2.81 (2.74–2.88) 2.98 (2.70–3.28) 2.73 (2.63–2.83) 3.47 (3.18–3.78) 2.89 (2.79–2.98) 0.95 (0.90–0.99) 0.02
Follicular 3.14 (2.94–3.35) 2.73 (2.66–2.79) 2.87 (2.59–3.17) 2.63 (2.54–2.73) 3.39 (3.10–3.71) 2.82 (2.72–2.91) 0.93 (0.89–0.98) 0.006
Follicular, large cell 0.13 (0.09–0.20) 0.09 (0.07–0.11) 0.12 (0.07–0.20) 0.10 (0.06–0.14) 0.15 (0.07–0.27) 0.07 (0.04–0.10) 1.44 (0.79–2.64) 0.235
Mantle cell 0.86 (0.76–0.98) 0.65 (0.62–0.69) 1.15 (0.98–1.34) 0.99 (0.93–1.05) 0.60 (0.48–0.74) 0.39 (0.35–0.42) 2.57 (2.30–2.88) o0.0001
BL 0.36 (0.29–0.44) 0.36 (0.32–0.39) 0.55 (0.43–0.69) 0.54 (0.47–0.61) 0.18 (0.12–0.27) 0.19 (0.14–0.23) 2.95 (2.30–3.78) o0.0001
Intermediate DLBCL/CHLa 0.22 (0.14–0.33) 0.08 (0.05–0.10) 0.29 (0.16–0.48) 0.11 (0.06–0.15) 0.16 (0.07–0.31) 0.05 (0.02–0.08) 2.30 (1.07–4.94) 0.003
CHL 2.58 (2.40–2.77) 2.49 (2.43–2.56) 2.89 (2.61–3.19) 2.82 (2.72–2.92) 2.29 (2.05–2.55) 2.20 (2.11–2.28) 1.28 (1.22–1.35) o0.0001
Nodular sclerosis CHL 1.91 (1.75–2.07) 1.87 (1.81–1.93) 2.04 (1.81–2.30) 2.01 (1.92–2.10) 1.78 (1.57–2.01) 1.75 (1.67–1.83) 1.15 (1.08–1.23) o0.0001
Mixed cellularity CHL 0.61 (0.52–0.70) 0.56 (0.52–0.60) 0.74 (0.60–0.89) 0.70 (0.64–0.77) 0.48 (0.38–0.61) 0.42 (0.37–0.48) 1.67 (1.43–1.96) o0.0001
Lymphocyte-rich CHL 0.13 (0.08–0.20) 0.07 (0.05–0.09) 0.13 (0.07–0.23) 0.11 (0.07–0.15) 0.11 (0.03–0.28) 0.03 (0.01–0.06) 3.49 (1.53–7.97) 0.003
Lymphocyte predominant nodular HL 0.37 (0.30–0.45) 0.34 (0.31–0.38) 0.52 (0.41–0.66) 0.52 (0.45–0.58) 0.20 (0.13–0.30) 0.18 (0.13–0.22) 2.96 (2.28–3.84) o0.0001
T-cell 1.08 (0.96–1.21) 0.92 (0.88–0.97) 1.24 (1.06–1.44) 1.14 (1.07–1.21) 0.92 (0.77–1.09) 0.74 (0.67–0.80) 1.55 (1.39–1.72) o0.0001
Peripheral—common, unspecified 0.32 (0.26–0.39) 0.27 (0.24–0.29) 0.41 (0.31–0.53) 0.37 (0.32–0.43) 0.23 (0.16–0.32) 0.17 (0.13–0.21) 2.25 (1.73–2.92) o0.0001
Angioimmunoblastic 0.22 (0.17–0.29) 0.15 (0.13–0.17) 0.19 (0.12–0.30) 0.13 (0.09–0.17) 0.24 (0.17–0.33) 0.17 (0.13–0.21) 0.77 (0.53–1.12) 0.169
Anaplastic large cell 0.17 (0.13–0.23) 0.14 (0.11–0.17) 0.23 (0.15–0.33) 0.19 (0.13–0.25) 0.12 (0.07–0.19) 0.10 (0.06–0.15) 1.82 (1.09–3.02) 0.020
ALK-negative 0.11 (0.07–0.16) 0.08 (0.06–0.10) 0.12 (0.07–0.20) 0.10 (0.06–0.13) 0.09 (0.05–0.16) 0.07 (0.03–0.10) 1.49 (0.76–2.93) 0.251
ALK-positive 0.08 (0.05–0.13) 0.06 (0.04–0.09) 0.10 (0.05–0.17) 0.09 (0.05–0.14) 0.05 (0.01–0.14) 0.04 (0.01–0.06) 2.97 (1.12–7.89) 0.029
Mycosis fungoides 0.16 (0.11–0.21) 0.12 (0.10–0.14) 0.23 (0.15–0.33) 0.18 (0.14–0.23) 0.09 (0.04–0.15) 0.07 (0.03–0.11) 2.69 (1.62–4.46) o0.0001
Primary cutaneous CD30þ LPD 0.14 (0.10–0.19) 0.13 (0.10–0.15) 0.14 (0.08–0.21) 0.13 (0.09–0.18) 0.14 (0.08–0.22) 0.12 (0.08–0.16) 1.10 (0.68–1.78) 0.707
Enteropathy-type 0.11 (0.07–0.17) 0.08 (0.07–0.10) 0.13 (0.07–0.21) 0.10 (0.07–0.13) 0.10 (0.05–0.18) 0.07 (0.04–0.10) 1.39 (0.81–2.40) 0.238
Abbreviations: ALK¼ anaplastic lymphoma kinase; BL¼Burkitt lymphoma; CI¼ confidence interval; CHL¼ classical Hodgkin lymphoma; DLBCL¼diffuse large B-cell lymphoma; FL¼ follicular lymphoma; IQR¼ interquartile range; LPD¼ lymphoproliferative disorders;
MZL¼marginal zone lymphoma; NOS¼not otherwise specified.
a
Cases classified 2009–2012 only.
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anaplastic large cell lymphoma (median diagnostic age 35.6 years)
which accounted for only 0.3%. Striking differences between males
and females in relation to their levels of disease occurrence and
ages at diagnosis were observed: males consistently tending to have
significantly higher age-standardised incidence rates and to be
diagnosed at younger ages, resulting in a doubling of the male/
female rate ratio for all lymphomas combined in those diagnosed
before 15 years of age. Such strong gender differences have a big
impact on prevalence; the combined lymphoma 10-year prevalence
estimate in our dataset being 30 per 100 000 higher in males than
in females. That haematological malignancies often occur more
frequently in males than females has been noted by others (Morton
et al, 2006); and in this regard subtypes that fail to exhibit these
incidence/age features stand out; follicular lymphoma being the
only mature B-cell lymphoma to occur significantly more
frequently in women than men and nodular sclerosis classical
Hodgkin lymphoma being the only one with a significantly
younger diagnostic age in females than males. Likewise, nearly all
Table 3. Lymphoma 5-year OS and RS estimates (95% confidence interval): Haematological Malignancy Research Network
(HMRN) diagnosed 2004–2012 and followed through to 2014
Total diagnoses Males Females
OS (95% CI) RS (95% CI) OS (95% CI) RS (95% CI) OS (95% CI) RS (95% CI)
All lymphomas 57.4 (56.0–58.7) 67.4 (65.9–68.9) 57.0 (55.1–58.8) 67.2 (65.0–69.2) 57.8 (55.8–59.7) 67.8 (65.5–69.9)
Non-Hodgkin 53.7 (52.2–55.2) 63.9 (62.2–65.6) 53.4 (51.3–55.4) 63.9 (61.5–66.1) 54.0 (51.9–56.2) 64.1 (61.6–66.5)
Hodgkin 78.9 (75.8–81.7) 84.9 (81.7–87.6) 77 (72.6–80.7) 82.3 (77.7–86.1) 81.5 (76.8–85.3) 87.7 (82.6–91.4)
B-cell 58.4 (57–59.8) 68.8 (67.2–70.3) 58.0 (56.0–59.9) 68.5 (66.3–70.6) 58.9 (56.8–60.9) 69.1 (66.8–71.3)
DLBCL 46.3 (44.2–48.4) 54.8 (52.4–57.1) 46.6 (43.6–49.5) 55.5 (52.0–58.8) 46.1 (43.0–49.1) 54.2 (50.7–57.5)
DLBCL, NOS 46.6 (44.4–48.7) 55.0 (52.6–57.4) 46.9 (43.9–49.9) 55.9 (52.4–59.2) 46.2 (43.1–49.2) 54.3 (50.8–57.7)
T-cell/histiocyte-rich 64.5 (45.1–78.5) 67.9 (46.8–82.0) 58.0 (31.7–77.3) 61.1 (32.5–80.5) 71.7 (41.1–88.3) 73.4 (41.1–89.8)
Plasmablastic 16.3 (4.8–33.7) 17.2 (5.1–35.5) 17.5 (3.2–41.1) 18.5 (3.4–43.2) 14.5 (1.8–39.4) 14.7 (1.8–40.0)
MZL 61.2 (57.7–64.5) 77.2 (72.9–80.8) 60.7 (55.9–65.1) 77.6 (71.5–82.5) 61.9 (56.6–66.7) 76.4 (69.9–81.7)
Systemic MZL 57.4 (53.4–61.2) 73.0 (68.0–77.4) 58.3 (52.9–63.3) 75.3 (68.3–80.9) 56.3 (50.0–62.1) 70.0 (62.1–76.5)
Extranodal MZL 74.7 (67.7–80.3) 87.9 (78.7–93.3) 70.3 (59.6–78.7) 83.6 (68.5–91.9) 78.8 (69.2–85.8) 89.9 (75.7–96.0)
FL 75.6 (72.4–78.5) 86.5 (83.0–89.4) 76.5 (71.6–80.7) 86.8 (81.2–90.9) 74.9 (70.5–78.8) 86.6 (81.5–90.4)
Follicular 75.2 (71.9–78.2) 86.3 (82.6–89.2) 75.8 (70.8–80.1) 86.4 (80.5–90.6) 74.7 (70.2–78.6) 86.5 (81.3–90.4)
Follicular, large cell 88.6 (68.6–96.2) 89.7 (68.0–97.0) 93.4 (61.4–99.0) 93.5 (61.0–99.1) 82.4 (46.0–95.3) 83.3 (45.0–95.9)
Mantle cell 25.0 (18.8–31.6) 31.4 (23.6–39.5) 29.2 (21.5–37.4) 36.8 (26.8–46.8) 16.3 (7.8–27.6) 20.2 (9.5–33.7)
BL 51.0 (40.9–60.2) 52.9 (42.4–62.4) 55.2 (43.3–65.6) 57.7 (45.1–68.4) 39.2 (21.4–56.7) 39.9 (21.7–57.6)
Intermediate DLBCL/CHLa 83.1 (61.0–93.3) 84.0 (61.0–94.0) 86.6 (56.2–96.5) 87.1 (55.7–96.8) 76.0 (33.3–93.4) 76.8 (32.7–94.0)
Classical Hodgkin (CHL) 76.5 (73.1–79.6) 82.5 (78.9–85.5) 73.6 (68.7–77.8) 78.7 (73.5–83.0) 80.0 (75.1–84.1) 86.5 (81.0–90.5)
Nodular sclerosis CHL 80.3 (76.5–83.5) 86.0 (82.0–89.2) 75.7 (69.9–80.6) 80.8 (74.5–85.7) 85.0 (79.9–88.9) 91.5 (85.5–95.1)
Mixed cellularity CHL 63.3 (55.3–70.3) 69.3 (60.3–76.7) 65.2 (54.8–73.8) 70.4 (58.7–79.3) 60.8 (47.7–71.7) 65.3 (50.7–76.5)
T-cell 39.5 (33.7–45.2) 45.4 (38.8–51.8) 40.8 (33.0–48.5) 46.8 (37.8–55.4) 37.8 (29.4–46.2) 42.2 (32.7–51.4)
Peripheral—common, unspecified 17.6 (10.3–26.5) 19.7 (11.5–29.5) 20.9 (11.1–32.9) 23.2 (12.2–36.3) 11.7 (3.5–25.3) 12.6 (3.7–27.1)
Angioimmunoblastic 24.2 (12.5–37.9) 26.2 (13.5–40.9) 29.5 (10.3–51.9) 31.0 (10.7–54.1) 23.2 (9.9–39.7) 24.8 (10.5–42.2)
Anaplastic large cell 46.5 (30.5–60.9) 50.8 (33.0–66.2) 40.7 (20.8–59.8) 43.7 (21.9–63.7) 55.1 (30.1–74.4) 57.4 (30.8–77.0)
ALK-negative 17.6 (10.3–26.5) 19.7 (11.5–29.5) 21.5 (3.8–48.6) 23.1 (3.9–51.7) 32.8 (10.2–58.0) 34.2 (10.4–60.1)
ALK-positive 75.0 (46.4–89.8) 75.2 (46.4–90.0) 66.7 (33.8–86.0) 66.8 (33.8–86.1) — —
Mycosis fungoides 77.8 (60.1–88.3) 86.6 (61.1–95.8) 77.5 (56.3–89.3) 82.4 (56.9–93.6) 78.0 (35.8–94.2) 82.2 (30.6–96.8)
Primary cutaneous CD30þ LPD 86.0 (69.5–94.0) 88.3 (69.7–95.8) 83.4 (56.7–94.4) 85.4 (55.7–95.8) 88.8 (62.2–97.1) 89.2 (61.7–97.4)
Enteropathy-type 27.2 (11.6–45.6) 28.0 (11.8–46.8) 28.1 (7.5–53.7) 28.8 (7.6–54.7) 23.9 (5.2–50.1) 24.3 (5.3–50.6)
Abbreviations: ALK¼ anaplastic lymphoma kinase; BL¼Burkitt lymphoma; CI¼ confidence interval; CHL¼ classical Hodgkin lymphoma; DLBCL¼diffuse large B-cell lymphoma; FL¼ follicular
lymphoma; IQR¼ interquartile range; LPD¼ lymphoproliferative disorders; MZL¼marginal zone lymphoma; NOS¼ not otherwise specified; OS¼overall survival; RS¼ relative survival.
a
Cases classified 2009–2012 only.
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Figure 3. Overall and relative survival by subtype: Haematological Malignancy Research Network (HMRN) 2004–2012.
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T-cell lymphomas occurred at significantly higher levels in males
than in females; however, no statistically significant differences
between males and females with respect to age at diagnosis were
observed. Unfortunately, ethnic differences could not be examined
for in the dataset as 95% of the population are Caucasian.
In contrast to the pronounced gender differences seen for
lymphoma occurrence and age at diagnosis, no statistically
significant survival differences between males and females were
detected—either overall or within any of the subtypes. This result
is in broad agreement with cancer registry findings from
EUROCARE-4, where close agreement between male and female
relative survival estimates in those diagnosed 2000–2002 was also
noted (Marcos-Gragera et al, 2011). Given the incorporation of
male sex into the Hasenclever prognostic score (Hasenclever and
Diehl, 1998), it is perhaps worth noting the borderline nature of
the overall and relative survival differences for the classical
Hodgkin lymphomas. For nodular sclerosis classical Hodgkin
lymphoma, the 5-year overall survival estimates for males and
females were 75.7 (95% CI 69.9–80.6) and 85.0 (95% CI 79.9–88.9)
respectively, and the 5-year relative survival estimates were slightly
closer at 80.8 (95% CI 74.5–85.7) and 91.5 (95% CI 85.5–95.1)
respectively. Interestingly, mixed cellularity classical Hodgkin
lymphoma shows a slight, but again not statistically significant,
bias in the other direction, the 5-year relative survival estimates
being 70.4 (95% CI 58.7–79.3) and 65.3 (95% CI 50.7–76.5)
respectively. When making such comparisons, it is important to
recall that most international prognostic scores are developed using
data either from trials or from selected groups of treated patients
(International Non-Hodgkin’s Lymphoma Prognostic Factors
Project, 1993; Hasenclever and Diehl, 1998; Solal-Ce´ligny et al,
2004). In the case of Hodgkin lymphoma, the Hasenclever was
based on patients aged 15–65 years who were treated for advanced
Hodgkin lymphoma with curative intent before 1992, and for
whom outcome was known (Hasenclever and Diehl, 1998).
Taken as whole, survival was generally better for B-cell
lymphomas than for T-cell lymphomas, the corresponding 5-year
relative survival estimates being 68.8% (95% CI 67.2–70.3) and
45.4% (38.8–51.8) respectively. However, both groups contain a
mix of comparatively indolent and aggressive disease forms, some
of which are curable and others of which are not. B-cell
lymphomas like follicular lymphoma and marginal zone, as well
as certain T-cell lymphomas like mycosis fungoides, often follow a
remitting/relapsing course that can include long periods without
treatment. Reflective of this pattern, the 5-year survival of patients
with these comparatively indolent, but currently incurable,
subtypes ranges between 75 and 90%. Wider survival variations
were, however, evident among the more aggressive lymphomas,
several of which tend to be treated with intensive first-line
chemotherapy regimens. In this regard, treatment for most of the
Hodgkin lymphomas was clearly extremely effective, with 5-year
relative survival estimates in excess of 80%. For other potentially
curable subtypes, like diffuse large B-cell and Burkitt’s, most deaths
occurred within the first year; and although the 5-year relative
survival was only 50%, the flattening of the curve after this point
implies that the mortality of patients who survive treatment is similar
to that of the general population. Currently, outcomes seem less
promising for other rarer lymphomas; including mantle cell where
the 5-year relative survival of around 30% continued to fall across
our 9 years of follow-up, as well as many of the T-cell lymphomas
where the common peripheral T-cell and ALK-negative anaplastic
large cell both had 5-year relative survival estimates below 20%.
Major strengths of our study include its large well-defined
catchment area, completeness of ascertainment and world-class
diagnostics. With respect to the latter, all lymphomas were
diagnosed and coded using the latest WHO oncology classification
by clinical specialists working at a single fully integrated
laboratory—the Haematological Malignancy Diagnostic Service
(HMDS). As one of the largest integrated haematopathology
laboratories in Europe, HMDS has a strong record of national/
international leadership in research in lymphoid malignancies, and
is cited by the UK’s National Institute for Health and Care
Table 4. Lymphoma 3, 5 and 10 year prevalence estimates (95% confidence interval) per 100,000: Haematological Malignancy
Research Network (HMRN) 2004–2012
Prevalence proportion per 100000
Total diagnoses Males Females
3-year 5-year 10-year 3-year 5-year 10-year 3-year 5-year 10-year
All lymphomas 48.0 (45.8–50.3) 72.5 (69.7–75.3) 123.7 (120.0–127.4) 53.6 (50.1–57.0) 81.0 (76.7–85.2) 138.3 (132.7–144.0) 42.8 (39.8–45.8) 64.5 (60.9–68.2) 109.9 (105.1–114.8)
Non-Hodgkin 39.9 (37.9–42.0) 59.9 (57.4–62.5) 100.1 (96.7–103.4) 43.6 (40.5–46.7) 65.5 (61.7–69.3) 109.7 (104.7–114.8) 36.5 (33.7–39.3) 54.7 (51.3–58.1) 91.0 (86.6–95.4)
Hodgkin 8.3 (7.3–9.2) 12.9 (11.7–14.0) 24.0 (22.4–25.6) 10.1 (8.6–11.6) 15.7 (13.9–17.6) 28.8 (26.3–31.3) 6.6 (5.4–7.7) 10.2 (8.7–11.6) 19.4 (17.4–21.4)
B-cell 46.2 (44.0–48.5) 69.9 (67.2–72.6) 119.5 (115.9–123.2) 51.4 (48.1–54.8) 77.7 (73.6–81.9) 133.1 (127.6–138.7) 41.3 (38.4–44.3) 62.5 (58.9–66.1) 106.8 (102.0–111.6)
Diffuse large B-cell 17.6 (16.2–18.9) 25.9 (24.2–27.5) 43.3 (41.1–45.5) 20.0 (17.9–22.1) 28.8 (26.3–31.4) 47.9 (44.5–51.2) 15.3 (13.5–17.0) 23.1 (20.9–25.3) 39.0 (36.1–41.9)
Marginal Zone 10.1 (9.0–11.1) 15.2 (13.9–16.5) 23.8 (22.2–25.4) 11.2 (9.6–12.8) 17.1 (15.1–19.0) 26.7 (24.2–29.2) 9.0 (7.6–10.4) 13.5 (11.8–15.1) 21.1 (18.9–23.2)
Follicular 9.7 (8.7–10.7) 14.8 (13.6–16.1) 25.2 (23.5–26.9) 8.6 (7.2–10.0) 13.6 (11.9–15.4) 24.1 (21.8–26.5) 10.7 (9.2–12.2) 16.0 (14.1–17.8) 26.2 (23.8–28.6)
Mantle cell 1.8 (1.3–2.2) 2.4 (1.9–2.9) 3.3 (2.7–4.0) 2.3 (1.6–3.0) 3.4 (2.5–4.2) 4.7 (3.7–5.8) 1.2 (0.7–1.8) 1.5 (1.0–2.1) 2.0 (1.4–2.7)
Burkitt 0.6 (0.4–0.9) 1.0 (0.7–1.4) 1.8 (1.4–2.3) 1.0 (0.5–1.4) 1.6 (1.0–2.1) 3.0 (2.1–3.8) 0.3 (0.0–0.5) 0.5 (0.2–0.9) 0.8 (0.4–1.2)
Classical Hodgkin 6.9 (6.1–7.8) 11.0 (9.9–12.1) 20.4 (18.9–21.9) 7.9 (6.5–9.2) 12.8 (11.1–14.5) 23.2 (20.9–25.5) 6.1 (5.0–7.2) 9.3 (7.9–10.7) 17.8 (15.9–19.8)
T-cell 1.8 (1.4–2.2) 2.6 (2.1–3.2) 4.3 (3.6–5.0) 2.1 (1.4–2.8) 3.2 (2.4–4.1) 5.2 (4.1–6.3) 1.5 (0.9–2.0) 2.1 (1.4–2.7) 3.4 (2.6–4.3)
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Figure 4. Mature B-cell lymphoma 3, 5, and 10 year prevalence
estimates by subtype: Haematological Malignancy Research Network
(HMRN) 2004–2012.
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Excellence (NICE) guidance as the model for service delivery
(Department of Health, 2007, 2011). This means that, as well as
having comprehensive accurate data, our patient cohort does not
suffer from the data quality issues commonly faced by non-
specialist population-based cancer registries (Sant et al, 2010,
2014). Hence, as can be seen from Table 5, although our incidence
and prevalence estimates for the traditional groupings of non-
Hodgkin lymphoma and Hodgkin lymphoma are reassuringly
similar to those calculated for the UK as a whole by the
International Agency for Research on Cancer’s EUCAN project
(http://eco.iarc.fr/eucan/) (Ferlay et al, 2013; Steliarova-Foucher
et al, 2014), our B-cell and T-cell age standardised (European) sub-
type incidence rates tend to be uniformly higher than those
estimated by non-specialist European cancer registries (Sant et al,
2010). This disparity is partly due to the fact that the range and
depth of data used to make the actual diagnosis are difficult for
many cancer registries to access systematically (Marcos-Gragera
et al, 2011), and so lymphomas are often registered using not
otherwise specified codes, such as lymphoma not otherwise
specified (9590) or non-Hodgkin lymphoma not otherwise
specified (9591) (Fritz, 2000). Similar not otherwise specified
levels for haematological cancers occur within SEER (Surveillance,
Epidemiology, and End Results, http://seer.cancer.gov/) registries
(Morton et al, 2006), where the use of a different standard
population (US 2000 census) adds to the difficulty of making
comparisons with European populations (Morton et al, 2006; Li
et al, 2015). The US 2000 standard has an older age distribution
than the European Standard, so its use results in a general increase;
our age-standardised rates (both sexes combined) for diffuse large
B-cell and marginal zone lymphomas, for example, increasing from
6.6 and 2.6 per 100 000 (European 2013) to 7.0 and 2.8 per 100 000
(US 2000), respectively.
In addition to affecting measures of disease occurrence, lack of
diagnostic specificity at the point of cancer registration also
impacts on survival estimates, where external validity may be
further reduced by the data exclusions that are frequently applied
(Li et al, 2014). It is not uncommon, for example, to exclude
patients when the date of diagnosis falls on the date of death; this
being a marker for registrations based on death certificates
only (Rachet et al, 2008). In our data, 140 (6.1%) of the
2300 deaths that occurred within 5 years of diagnosis happened
on the day of diagnosis, and clearly omission of such deaths would
have led to biased estimates. The 5-year relative survival estimates
for diffuse large B-cell lymphoma would, for example, have
increased by around 3% from 54.8 (95% CI 52.4–57.1) to 57.6
(95% CI 55.1–60.0) had the 101 deaths that occurred on the day of
diagnosis been excluded. Comparisons with clinical trials, which by
design usually focus on treated patients in specific subgroups, are
equally challenging. Hence, in the general patient population,
survival estimates for the more aggressive lymphomas like diffuse
large B-cell will tend to be lower than those observed in phase III
randomised controlled trials (Cunningham et al, 2013); whereas
those for the more indolent lymphomas like follicular, which may
be actively monitored rather than treated with chemotherapy, will
tend to be higher (Press et al, 2013).
In summary, our contemporary population-based analyses of
incidence, prevalence and survival of lymphomas categorised by
WHO subtype provides valuable information for researchers,
clinicians and patients. Marked variations by subtype, age and sex
were demonstrated; confirming that ‘real-world’ data are required
not only to better inform aetiological hypotheses and plan future
health-care services, but also to monitor the impact of therapeutic
changes at the population level.
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